Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 14, 2011

FDA grants orphan drug status to Santen Sirolimus drug

The US Food and Drug Administration (FDA) has issued orphan drug status for Santen's sirolimus (DE-109, rapamycin) drug as a treatment for chronic / refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis and non-infectious uveitis affecting the posterior segment of the eye.

The US Food and Drug Administration (FDA) has issued orphan drug status for Santen’s sirolimus (DE-109, rapamycin) drug as a treatment for chronic / refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis and non-infectious uveitis affecting the posterior segment of the eye.

Sirolimus, an immunosuppressive and anti-proliferative agent, is being evaluated in a study assessing double-masked uveitis treatment (SAKURA) Phase III study to demonstrate the safety and efficacy of different doses of sirolimus in non-infectious posterior uveitis.

The move follows the approval of orphan drug status by the European Commission in September 2011.

The orphan drug designation programme is intended to advance the investigation and development of drugs that demonstrate promise for the diagnosis and / or treatment of rare diseases or conditions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU